Search
for
Sort by
Research 421–450 of 1000+
- HLA‐B alleles associated with frontal fibrosing alopecia in Brazil may share similar peptide presentation and T‐cell interaction profiles
- Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
- Pustular allergic contact dermatitis from minoxidil
- Characterization of a mouse Scube3 reporter line
- Intracranial hypertension as the first manifestation of systemic lupus erythematosus: A case report
- Comparative study of photobiomodulation and low frequency on the body contour: controlled, randomized, double blind clinical trial
- Avaliação in vitro da segurança e eficácia de nutracêutico à base de alecrim para a pele de cães
- INFLUENCE OF LIFESTYLE ON THE PROGNOSIS OF POLYCYSTIC OVARY SYNDROME
- Efeitos da ingestão de cafeína durante a gestação e a lactação sobre a pele de ratas e de filhotes e sua relação com as concentrações séricas do cortisol materno
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Alopecia areata: a review of disease pathogenesis
- Immune Privilege Collapse and Alopecia Development: Is Stress a Factor
- A Practical Approach to the Diagnosis and Management of Hair Loss in Children and Adolescents
- The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern
- Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study
- Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
- The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Dupilumab‐induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review
- Spironolactone for treatment of female pattern hair loss
- Hair repigmentation associated with the use of brentuximab
- The Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
- Comorbidities in patients with lichen planopilaris: A retrospective case-control study
- Androgenetic Alopecia in Gender Minority Patients
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
- Hair loss among transgender and gender‐nonbinary patients: a cross‐sectional study
- Patterns of insurance coverage for wigs in patients with alopecia areata: a cross-sectional survey
- Development and validation of the Brigham Eyelash Tool for Alopecia (BELA): A measure of eyelash alopecia areata